Shilpa Hattangadi, MD

Assistant Professor of Pediatrics (Hematology / Oncology) and of Pathology; Assistant Professor, Pathology

Departments & Organizations

Pediatrics: Pediatric Hematology & Oncology

Pathology: Experimental Pathology Graduate Program

Center for Biomedical Data Science

Yale Cancer Center: Genomics, Genetics, and Epigenetics | Pediatric Hematology & Oncology Program

Yale Combined Program in the Biological and Biomedical Sciences (BBS): Molecular Cell Biology, Genetics and Development | Molecular Medicine, Pharmacology, and Physiology

Yale Medicine

Yale Stem Cell Center

Office of Cooperative Research


Shilpa Hattangadi has an Electrical Engineering and Computer Science undergraduate degree from MIT. Her postdoctoral work at the Whitehead Institute in Harvey Lodish's lab spurred an interest in applying fundamental molecular biology to intriguing concenpts in red blood cell development. Her initial work on the dynamics of chromatin modifications during erythroid transcription transformed into a focus on erythroid nuclear development. Our laboratory now centers on the dynamics of chromatin during normal terminal erythroid differentiation, specifically chromatin condensation and enucleation, which is specific to mammalian red cell development, as well as the role of certain chromatin modifiers on erythroid nuclear development in diseases such as myelodysplastic syndrome (MDS).

Education & Training

MD Duke University Medical Center, Medicine (1999)
BS Massachusetts Institute of Technology, Electrical Engineering/Biology (1995)
Postdoctoral Fellow Whitehead Institute for Biomedical Research
Fellowship Boston Children's Hospital/Dana Farber Cancer Center
Residency Johns Hopkins Hospital

Edit this profile

Contact Info

Shilpa Hattangadi, MD
Patient Care Location
Pediatric Hematology & OncologySmilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 7th floor

New Haven, CT 06511
View on map...
Mailing Address
Pediatric Hematology & OncologyPediatric Hematology-Oncology
333 Cedar Street

New Haven, CT 06520
Erythroid Terminal Differentiation

A set number of characteristic cell divisions (3 in mouse, 4 in humans) from the progenitor to the final erythroblast result in decreased cell size. A distinct expression program results in hemoglobin production, making the cytoplasm more eosinophilic. Nuclear condensation ensues and culminates in enucleation only in mammals. We study this last step of terminal erythropoiesis.